Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 25
- Registration Number
- NCT01353833
- Locations
- 🇫🇷
Hôpital Pitié-Salpêtrière, Paris, France
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
- Conditions
- Metastatic MelanomaSkin Cancer
- Interventions
- Radiation: Total Body Irradiation (TBI)
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 102
- Registration Number
- NCT01319565
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
- Conditions
- Metastatic CancerMetastatic Renal CancerMetastatic Melanoma
- Interventions
- Biological: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01273181
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drosophila-generated CTL
- Conditions
- Metastatic Cutaneous Melanoma
- Interventions
- Drug: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01271907
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- Conditions
- Metastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Ovarian CancerMetastatic Breast CarcinomaMetastatic Endocrine Tumors/ Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 332
- Registration Number
- NCT01174121
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
- Conditions
- Metastatic MelanomaMetastatic Renal Cancer
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01160445
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Stage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7Clear Cell Renal Cell CarcinomaMetastatic Kidney Carcinoma
- Interventions
- Procedure: Computed TomographyRadiation: Fludeoxyglucose F-18Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyProcedure: Positron Emission Tomography
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT01038778
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
- Conditions
- Renal CancerKidney Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00923390
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
- Conditions
- MelanomaMalignant MelanomaMelanoma, Experimental
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT00924001
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
- Conditions
- Diffuse, Large B-cell LymphomaMantle CellPrimary Mediastinal B-cell LymphomaDiffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
- Interventions
- Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT00924326
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.